High-dose @entity1499 as secondary chemotherapy in metastatic soft-tissue XXXX .

@entity1 @entity137 @entity242 @entity5426 @entity3 @entity1499 @entity204
High-dose @entity1499 in a dose of 2-4 g/m2 every four weeks was given as secondary chemotherapy to 22 @entity1 with metastatic soft-tissue @entity242 ; toxic reactions included 1 @entity204 and 2 instances of moderate @entity137 . The remaining @entity1 tolerated this treatment without difficulty. Of 18 @entity1 with measurable evaluable disease, 17 demonstrated progression. One @entity1 with @entity5426 had a complete response lasting for 15 months. Three @entity1 were given adjuvant high-dose @entity1499 following wedge resections of pulmonary @entity3 . One @entity1 demonstrated recurrence after four months, another after 13 months, and the third after 15 months. One additional @entity1 underwent resection of pulmonary @entity3 following two months of stabilization with high-dose @entity1499 and has continued free of disease with high-dose @entity1499 as adjuvant for eight months. Five @entity1 are alive and have been disease-free for an average period of 14 months. Four of these underwent operative treatment combined with chemotherapy. The effectiveness of high-dose @entity1499 appears limited in soft-tissue @entity242 when it is given as secondary chemotherapy.
